Autoimmune response to PARP and BRCA1/BRCA2 in cancer

Qing Zhu; Su-Xia Han; Cong-Ya Zhou; Meng-Jiao Cai; Li-Ping Dai; Jian-Ying Zhang

doi:10.18632/oncotarget.3428

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Autoimmune response to PARP and BRCA1/BRCA2 in cancer

Qing Zhu _, Su-Xia Han, Cong-Ya Zhou, Meng-Jiao Cai, Li-Ping Dai and Jian-Ying Zhang

PDF | HTML | How to cite

Oncotarget. 2015; 6:11575-11584. https://doi.org/10.18632/oncotarget.3428

Metrics: PDF 1953 views | HTML 2549 views | ?

Abstract

Qing Zhu1,2, Su-Xia Han1, Cong-Ya Zhou1, Meng-Jiao Cai1, Li-Ping Dai2, Jian-Ying Zhang2

1Department of Oncology, The First Affiliated Hospital of Xi’an Jiaotong University Medical Center, Xi’an, Shaanxi, P.R. China

2Department of Biological Sciences, The University of Texas at El Paso, El Paso, Texas, USA

Correspondence to:

Qing Zhu, e-mail: [email protected]

Jian-Ying Zhang, e-mail: [email protected]

Keywords: autoantibody, DNA repair enzyme poly (ADP-Ribose) polymerase 1 (PARP1)/BRCA1/BRCA2, synthetic lethality, tumor-associated antigen (TAA), autoimmune

Received: January 05, 2015 Accepted: February 24, 2015 Published: March 24, 2015

ABSTRACT

Purpose: To determine the role of autoantibodies to PARP1 and BRCA1/BRCA2 which were involved in the synthetic lethal interaction in cancer.

Methods: Enzyme-Linked Immunosorbent Assay (ELISA) was used to detect autoantibodies to PARP1 and BRCA1/BRCA2 in 618 serum samples including 131 from breast cancer, 94 from lung cancer, 34 from ovarian cancer, 107 from prostate cancer, 76 from liver cancer, 41 from pancreatic cancer and 135 from normal individuals. The positive sera with ELISA were confirmed by Western blot. Immunohistochemistry was used to examine the expression of PARP1 and BRCA1/BRCA2 in breast cancer.

Results: Autoantibody frequency to PARP1, BRCA1, and BRCA2 in cancer varied from 0% to 50%. When the sera from cancer patients were tested for the presence of autoantibodies to PARP1 and BRCA1/BRCA2, the autoantibody responses slightly decreased and the positive autoantibody reactions varied from 0% to 50.0%. This was significantly higher autoantibody responses to PARP1 and BRCA1/BRCA2 (especially to PARP1 and BRCA1) in ovarian cancer and breast cancer compared to normal control sera (P < 0.001 and P < 0.01). Immunohistochemistry indicated that Pathology Grade at diagnosis to PARP1 expression in breast cancer was different (P < 0.05).

Conclusions: Different cancers have different profiles of autoantibodies. The autoantibodies to proteins involving the synthetic lethal interactions would be novel serological biomarker in some selective cancers.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3428

Publication Alerts

Research Papers:

Autoimmune response to PARP and BRCA1/BRCA2 in cancer

Abstract